ArticleJournal of molecular histology2026
Quercetin and hesperidin attenuate cyclophosphamide-induced renal injury in rats.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide (CP) is an effective chemotherapeutic agent whose clinical use is limited by nephrotoxicity associated with oxidative stress and inflammation. This study investigated the potential nephroprotective effects of quercetin (QUE) and hesperidin (HSP) against CP-induced renal injury in rats. Thirty-six male Wistar albino rats were randomly assigned to six groups (n = 6): Control, QUE, HSP, CP, QUE + CP, and HSP + CP. QUE and HSP were administered orally at a dose of 100 mg/kg/day for 15 days. CP (200 mg/kg) was administered intraperitoneally on the final day to induce nephrotoxicity. Renal function was assessed using serum biochemical parameters (urea, uric acid, creatinine, blood urea nitrogen [BUN], albumin, and total protein), oxidative stress was evaluated by measuring renal antioxidant enzyme activities (superoxide dismutase [SOD], catalase [CAT], glutathione peroxidase [GPx], and glutathione S-transferase [GST]) together with malondialdehyde (MDA) levels, and histopathological alterations were examined using hematoxylin-eosin staining. CP administration significantly increased serum urea, uric acid, creatinine, blood urea nitrogen, and total protein levels (all p < 0.05). It also increased renal MDA levels (p < 0.001) while reducing SOD (p < 0.05), CAT (p < 0.05), GPx (p < 0.001), and GST (p < 0.001) activities, accompanied by marked histopathological damage characterized by glomerular degeneration, tubular injury, hemorrhage, and inflammatory cell infiltration. Pretreatment with QUE or HSP significantly attenuated these alterations (all p < 0.05). Both flavonoids improved renal biochemical parameters, restored antioxidant defense mechanisms, reduced MDA levels, and ameliorated histopathological alterations compared with the CP group. Although QUE showed numerically greater improvements across several outcomes, direct statistical superiority over HSP was not demonstrated. QUE and HSP exert protective effects against CP-induced nephrotoxicity by reducing oxidative damage and preserving renal tissue integrity. These findings suggest that flavonoid-based adjunctive interventions may represent a promising strategy for reducing chemotherapy-associated renal injury and warrant further mechanistic and translational investigation.
Indexed as
Identifiers
42562927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.